PRT1419
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma
Conditions
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
Trial Timeline
Aug 11, 2021 → Feb 6, 2023
NCT ID
NCT04837677About PRT1419
PRT1419 is a phase 1 stage product being developed by Prelude Therapeutics for Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04837677. Target conditions include Sarcoma, Melanoma, Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04837677 | Phase 1 | Completed |
| NCT04543305 | Phase 1 | Completed |
Competing Products
20 competing products in Sarcoma